BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ogawa F, Oi Y, Nakajima K, Matsumura R, Nakagawa T, Miyagawa T, Sakai K, Saji R, Taniguchi H, Takahashi K, Abe T, Iwashita M, Nishii M, Takeuchi I. Temporal change in Syndecan-1 as a therapeutic target and a biomarker for the severity classification of COVID-19. Thromb J 2021;19:55. [PMID: 34399775 DOI: 10.1186/s12959-021-00308-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Q, Ye Z, Bignotti A, Zheng XL. Longitudinal Assessment of Plasma Syndecan-1 Predicts 60-Day Mortality in Patients with COVID-19. J Clin Med 2023;12. [PMID: 36675479 DOI: 10.3390/jcm12020552] [Reference Citation Analysis]
2 Zhang Q, Ye Z, McGowan P, Jurief C, Ly A, Bignotti A, Yada N, Zheng XL. Effects of convalescent plasma infusion on the ADAMTS13-von Willebrand factor axis and endothelial integrity in patients with severe and critical COVID-19. Res Pract Thromb Haemost 2022;:100010. [PMID: 36531671 DOI: 10.1016/j.rpth.2022.100010] [Reference Citation Analysis]
3 Harriott NC, Ryan AL. Proteomic profiling identifies biomarkers of COVID-19 severity.. [DOI: 10.1101/2022.11.29.518411] [Reference Citation Analysis]
4 Kozłowski P, Śmiarowski M, Przyborska W, Zemlik K, Małecka-giełdowska M, Leszczyńska A, Garley M, Ciepiela O. Mild-to-Moderate COVID-19 Convalescents May Present Pro-Longed Endothelium Injury. JCM 2022;11:6461. [DOI: 10.3390/jcm11216461] [Reference Citation Analysis]
5 Joffre J, Rodriguez L, Matthay ZA, Lloyd E, Fields AT, Bainton RJ, Kurien P, Sil A, Calfee CS, Woodruff PG, Erle DJ, Hendrickson C, Krummel MF, Langelier CR, Matthay MA, Kornblith LZ, Hellman J; COVID-19 Multi-Phenotyping for Effective Therapies (COMET) Consortium, COVID-19 Associated Coagulopathy, Inflammation, and Thrombosis (Co-ACIT) Study Group. COVID-19-associated Lung Microvascular Endotheliopathy: A "From the Bench" Perspective. Am J Respir Crit Care Med 2022;206:961-72. [PMID: 35649173 DOI: 10.1164/rccm.202107-1774OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Hetland G, Fagerhol MK, Dimova-Svetoslavova VP, Mirlashari MR, Nguyen NT, Lind A, Kolset SO, Søraas AVL, Nissen-Meyer LSH. Inflammatory markers calprotectin, NETs, syndecan-1 and neopterin in COVID-19 convalescent blood donors. Scand J Clin Lab Invest 2022;:1-5. [PMID: 36151851 DOI: 10.1080/00365513.2022.2123387] [Reference Citation Analysis]
7 Vásquez V, Orozco J. Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine. Anal Bioanal Chem 2023;415:1003-31. [PMID: 35970970 DOI: 10.1007/s00216-022-04237-7] [Reference Citation Analysis]
8 Patterson EK, Cepinskas G, Fraser DD. Endothelial Glycocalyx Degradation in Critical Illness and Injury. Front Med (Lausanne) 2022;9:898592. [PMID: 35872762 DOI: 10.3389/fmed.2022.898592] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fels B, Acharya S, Vahldieck C, Graf T, Käding N, Rupp J, Kusche-Vihrog K. Mineralocorticoid receptor-antagonism prevents COVID-19-dependent glycocalyx damage. Pflugers Arch 2022. [PMID: 35867189 DOI: 10.1007/s00424-022-02726-3] [Reference Citation Analysis]
10 Zha D, Fu M, Qian Y. Vascular Endothelial Glycocalyx Damage and Potential Targeted Therapy in COVID-19. Cells 2022;11:1972. [PMID: 35741101 DOI: 10.3390/cells11121972] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Maldonado F, Morales D, Díaz-Papapietro C, Valdés C, Fernandez C, Valls N, Lazo M, Espinoza C, González R, Gutiérrez R, Jara Á, Romero C, Cerda O, Cáceres M. Relationship Between Endothelial and Angiogenesis Biomarkers Envisage Mortality in a Prospective Cohort of COVID-19 Patients Requiring Respiratory Support. Front Med (Lausanne) 2022;9:826218. [PMID: 35372407 DOI: 10.3389/fmed.2022.826218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Tóth G, Pál D, Sugár S, Kovalszky I, Dezső K, Schlosser G, Drahos L, Turiák L. Expression of glycosaminoglycans in cirrhotic liver and hepatocellular carcinoma-a pilot study including etiology. Anal Bioanal Chem 2022. [PMID: 35344068 DOI: 10.1007/s00216-022-04025-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]